Novo Nordisk invests USD470M to expand GLP-1 tablet production in Ireland

IRELAND—Novo Nordisk, the Denmark-based pharmaceutical giant, has committed to investing 432 million euros (approximately USD 470 million; DKK 3.2 billion) in its manufacturing facility in Monksland, Athlone, Ireland.

This substantial investment marks a pivotal moment for the company as it seeks to expand its production capabilities for oral GLP-1 treatments, responding to growing global demand for these innovative medications.

Strategic expansion in Ireland

The tabletting facility in Athlone represents a cornerstone of Novo Nordisk’s long-term strategy to strengthen its presence in Ireland and enhance its global manufacturing footprint.

Through this investment, the company will significantly upgrade and retrofit its existing operations, thereby establishing the nation as a critical hub for serving markets beyond the United States.

The modernized facility will enable Novo Nordisk to manufacture oral GLP-1 products with greater efficiency while maintaining the highest quality standards demanded by healthcare providers and patients worldwide.

The expansion reflects Novo Nordisk’s confidence in Ireland’s skilled workforce and its strategic location within Europe.

By concentrating oral product manufacturing at this site, the company ensures it can effectively distribute medications to international markets while strengthening its domestic operations in the country where it has deep roots.

Enhanced production capabilities

The upgrade project will equip Novo Nordisk with advanced manufacturing capabilities specifically designed for oral pharmaceutical products.

This enhancement allows the company to address the substantial increase in demand for GLP-1 treatments, which have transformed the landscape of diabetes and obesity management in recent years.

The facility’s modernization will incorporate state-of-the-art technology and sustainable practices, positioning the company to meet both current patient needs and anticipated future requirements.

Kasper Bødker Mejlvang, executive vice president of Chemistry, Manufacturing and Controls & Product Supply at Novo Nordisk, emphasised the significance of this investment for the organisation’s future.

He noted that the expanded production capacity at the Athlone facility will strengthen the company’s ability to serve patients outside the United States with consistent, high-quality oral GLP-1 medications.

Mejlvang also highlighted that this project represents a historic milestone for Novo Nordisk in Ireland, underscoring the company’s unwavering commitment to its employees and to advancing treatment options for millions of individuals living with serious chronic diseases.

Job creation and local impact

The construction and expansion projects, which have already commenced, will generate substantial economic benefits for the Athlone region.

The company expects to create up to 500 construction jobs as the upgrade work progresses across the 45-acre (18-hectare) site.

These positions will support the comprehensive modernization efforts scheduled to conclude gradually between the end of 2027 and throughout 2028.

The facility’s existing 260 employees will continue to play a vital role in operations, focusing on delivering the highest-quality oral treatments to patients in an efficient and environmentally sustainable manner.

This commitment to both product excellence and environmental responsibility reflects Novo Nordisk’s broader corporate values and its dedication to responsible business practices.